The mission of Targos Molecular Pathology reflects the company’s core business:

Highly standardized clinical biomarker services for the developments of international pharmaceutical and diagnostic industry.

Predicting the response to pharmaceutical treatments has become increasingly important for three main reasons:

First, it is highly ethical to differentiate the patients with the most benefit from a drug from those who predictably will have no benefit.

Second, health care professionals and health care providers worldwide need diagnostic guidance how to handle the mismatch between innovative high value medicines and limited financial resources.

Third, it is an economic advantage for the pharmaceutical industry to stratify patient populations in clinical drug development and stratification thus helps to increase medical innovation.

For these main reasons the U.S. Food and Drug Administration in March 2005 has issued a draft guidance which requests the submission of all available validated biomarker data to any application for a new drug, which further sparked research and development activities in the field of biomarkers.

The instruments to address all these challenges are validated predictive biomarkers.

Founded in 2005 in Kassel, Germany, Targos used the knowledge and experience of its core team to apply, discover and validate highly standardized predictive biomarkers in human medicine. In addition Targos  distributes knowledge about biomarker application among health professionals in training courses.